Thursday, April 2, 2020

 

09.00                             Registration Opens

 

11.00 – 11.10              Welcome Address

                                         Michael von Bergwelt

11.10 – 13.30              Plenary Symposium 1: Emerging Concepts / New Agents

                                       Chair: Mario Sznol, Christoph Zielinski

 

11.10 - 11.30                 Myeloid immune checkpoint inhibition 

                                        Timo K. van den Berg, Amsterdam, The Netherlands

                         

11.30 - 11.50                 Potential of ADAR Pathway in immunotherapy

                                        Jeffrey Ishizuka, Boston, MA, USA

 

11.50 - 12.10                 The Stimulator of Interferon Genes (STING) pathway. Emerging clinical data 

                                        Reinhard Dummer, Zurich, Switzerland

 

12.10 - 12.30                  Neoadjuvant in melanoma: a new model for testing new strategies for improving efficacy

                                         Christian Blank, Amsterdam, The Netherlands

 

12.30 - 12.50                 CXCR3 required for anti-PD-1 efficacy

                                        Melvyn Chow, Boston, MA, USA

 

12.50 - 13.10                 IL-15 for cancer therapy

                                        Mark Rubinstein, Charleston, SC, USA

 

13.10 - 13.30                  T cell bispecific antibodies (4-1BB and tumor antigen)

                                         Pablo Umana, Zurich, Switzerland

 

13.30 – 14.30              Lunch

 

14.30 – 16.10              Plenary Symposium 2: Microbiome and immunotherapy

                                       Chair: Volkmar Nüssler, Giorgio Trinchieri

14.30 – 14.50                Microbiome and Immunotherapy in Cancer

                                        Giorgio Trinchieri, Bethesda, MD, USA

14.50 - 15.10                 Computational metagenomics for uncovering the unexplored microbiome diversity

                                        Nicola Segata, Trento, Italy


15.10 - 15.30                 Microbiome modulation for cancer therapy

                                      Hendrik Poeck, Munich, Germany


15.30 - 15.50                 Microbiome and epithelial cell stress in colon cancer

                                        Dirk Haller, Munich, Germany

15.50 - 16.10                 Microbiome modulation in HSC transplantation

                                        Marcel van den Brink, New York, NY, USA

16.10 – 16.40              Coffee Break

 

16.40 – 19.10              Plenary Symposium 3: Tumor microenvironment

                                        Chair: Paolo Ascierto, Eric Tartour

 

16.40 - 17.00                 Cancer immunotherapy strategies based on overcoming barriers within the tumor 

                                      microenvironment

                                        Tom Gajewski, Chicago, IL, USA

 

17.00 - 17.20                Immunoscore as possible predictive marker of response to treatments

                                       Franck Pagès, Paris, France

17.20 - 17.40                Tumor intrinsic vs tumor extrinsic immune suppression 

                                       Kai Wucherpfennig, Boston, MA, USA

 

17.40 - 18.00                Arming oncolytic viruses for DC activation and recruitment in melanoma

                                       T.D. de Gruijl, Amsterdam, The Netherlands

 

18.00 - 18.20                Dissecting the interplay between tumor cells and the immune system in melanoma                                                       progression and response to therapy

                                       Marisol Soengas, Madrid, Spain

 

18.20 - 18.40                Pancreatic Cancer Tumor Microenvironment

                                       Lei Zheng, Baltimore, MD, USA

 

18.40 - 18.55                Speaker 7 – from submitted abstracts

18.55 - 19.10                Speaker 8 – from submitted abstracts

 

19.10 – 22.00            Welcome Reception and Poster Viewing (at the venue)

Friday, April 3, 2020

 

08.30 – 09.30             Plenary Symposium 4: Vaccine Therapy

                                       Chair: Barbara Seliger, Lei Zheng

08.30 - 08.50                Mucosal vaccinations for cancer treatment 

                                      Georg Stary, Vienna, Austria

 

08.50 - 09.10                Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma

                                       Lisa Butterfield, San Francisco, CA, USA

 

09.10 - 09.30                Vaccine therapy in reversing anti -PD1 resistance

                                       Samir Khleif, Washington, DC, USA

 

09.30 – 10.30            Pro & Contra Session:

                                     Blinatumomab vs anti-CD19 CAR T cells: which treatment should be preferred and when?

                                       Can we treat with either regimen after relapse on the other?

                                     Chair: Wolfgang Herr

09.30 – 10.00               Pro Bite

                                       Max Topp, Würzburg, Germany

10.00 – 10.30               Pro CAR

                                       Marion Subklewe, Munich, Germany

10.30 – 11.00             Coffee Break

 

11.00 – 12.30             Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

                                      Chair: Lisa Butterfield, José Saro

11.00 – 11.20               High dimensional Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

                                       Pier Federico Gherardini, San Francisco, CA, USA

 

11.20 – 11.40               Hyperprogressive disease in patients treated with Immune checkpoint inhibitors

                                       Giuseppe Lo Russo, Milan, Italy

 

11.40 - 12.00                Novel splice isoforms, target for immunotherapy

                                       Jacques Banchereau, Bar Harbor, ME, USA

 

12.00 – 12.15               Speaker 4 – from submitted abstracts

 

12.15 – 12.30               Speaker 5 – from submitted abstracts

 

12.30 – 14.00             Lunch

 

14.00 – 15.00             Satellite Symposium

15.00 – 15.45             Lifetime Achievement Award

                                      Chair: Michael von Bergwelt

                                        The 34th anniversary of interleukin 6; a major player in inflammation, autoimmunity and

                                      cancer

                                        Toshio Hirano, Chiba, Japan

15.45 – 16.15             Coffee Break

16.15 – 17.10             Plenary Symposium 6: “Lost in Translation”

                                        Chair: Philipp Beckhove, Alfred Zippelius

16.15 – 16.35                Ups and downs of IDO inhibition in cancer treatment

                                        George Prendergast, Philadelphia, PA, USA

 

16.35 – 16.55                Why adoptive T cell therapies fail solid tumors?

                                        Sebastian Kobold, Munich, Germany

 

16.55 – 17.10                Speaker 3 – from submitted abstracts

 

17.10 – 18.10              Plenary Symposium 7: Young Researcher Session

                                        Chair: Sebastian Kobold, Zihai Li

 

17.10 – 17.25                Speaker 1 - from submitted abstracts

17.25 – 17.40                Speaker 2 - from submitted abstracts

17.40 – 17.55                Speaker 3 - from submitted abstracts

17.55 - 18.10                 Speaker 4 - from submitted abstracts

 

19.30                            ITOC7 Conference Dinner

 

Saturday, April 4, 2020

 

08.00 – 09.05              Plenary Symposium 8: Cell Therapy in Solid Tumors

                                      Chair: Christian Blank, Pedro Romero

08.00 – 08.20                Challenges of T-cell therapy in solid tumors

                                        Cassian Yee, Houston, TX, USA

 

08.20 – 08.35                Novel CAR formats for solid tumors 

                                         Hidde Ploegh, Boston, MA, USA

08.35 – 08.50                Novel strategies to enable T cell therapy of cancer

                                        Per Thor Straten, Herlev, Denmark

 

08.50 – 09.05                CAR T cell therapy in non hematological pediatric cancer

                                        Franco Locatelli, Rome, Italy

 

09.05 – 10.20             Plenary Symposium 9: Cell Therapy in Haematologic Diseases

                                      Chair: Florian Bassermann, Hinrich Abken

09.05 – 09.25                Cell therapy of hematological malignancies

                                        Chiara Bonini, Milan, Italy

                                          

09.25 – 09.45                New targets and technologies for CAR-T

                                        Michael Hudecek, Würzburg, Germany

 

09.45 – 10.05                Genome edited T cells for leukaemia

                                        Waseem Quasim, London, United Kingdom

 

10.05 - 10.20                 Speaker 4 – from submitted abstracts

 

10.20 – 10.50              Coffee Break

 

10.50 – 13.15              Plenary Symposium 10: Combination Therapy

                                      Chair: Michael Bergmann, Samir Khleif

10.50 – 11.10                 Combination of innate immune stimulation with immune check point blockade for 

                                       cancer therapy

                                         Simon Heidegger, Munich, Germany

 

11.10 - 11.30                  Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer

                                         Marleen Kok, Amsterdam, The Netherlands

 

11.30 - 11.50                  Targeting the tumour microenvironment through co-neutralization of IL-1beta and PD-1 to                                           attenuate MRD

                                         Ron-Nathan Apte, Beer Sheva, Israel

11.50 - 12.10                  Targeting immunosuppressive adenosine pathway in cancer 

                                         Rakesh Kumar, Gaithersburg, MD, USA

12.10 - 12.30                  GARP-directed cancer immunotherapy: mechanisms and opportunities

                                         Zihai Li, Columbus, OH, USA

12.30 – 12.45                 Speaker 6 – from submitted abstracts

12.45 - 13.00                  Speaker 7 – from submitted abstracts

13.00 - 13.15                  Speaker 8 – from submitted abstracts

 

13.15 - 13.30               Best Poster Awards & Closing Remarks

                                      Chair: Volkmar Nüssler

13.30 - 14.30               Lunch

© 2019 WMA GmbH - ITOC7     |     Data Protection Policy

  • Twitter - Grau Kreis